Free tool
FAERS Monitor: Focalin Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021802 or its brand name (Focalin Xr, Dexmethylphenidate Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
4,283
Serious
1,583
37% of reports
Hospitalization
406
Death reported
36
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective769
- nausea206
- anxiety199
- headache188
- fatigue176
- abnormal behaviour168
- feeling abnormal167
- decreased appetite160
- disturbance in attention158
- off label use150
- insomnia147
- aggression144
- depression141
- vomiting141
- dizziness130
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 14 |
| 2005 | 31 |
| 2006 | 78 |
| 2007 | 82 |
| 2008 | 82 |
| 2009 | 83 |
| 2010 | 82 |
| 2011 | 114 |
| 2012 | 125 |
| 2013 | 116 |
| 2014 | 149 |
| 2015 | 394 |
| 2016 | 420 |
| 2017 | 313 |
| 2018 | 245 |
| 2019 | 277 |
| 2020 | 242 |
| 2021 | 177 |
| 2022 | 244 |
| 2023 | 303 |
| 2024 | 263 |
| 2025 | 258 |
| 2026 | 191 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,876 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| abnormal behaviourSignal | 168 | 20.9 | 18.0 | 3,158 |
| disturbance in attentionSignal | 158 | 14.4 | 12.4 | 1,960 |
| aggressionSignal | 144 | 14.2 | 12.1 | 1,748 |
| anxietySignal | 199 | 3.4 | 3.0 | 346 |
| feeling abnormalSignal | 167 | 3.4 | 3.0 | 287 |
| decreased appetiteSignal | 160 | 3.4 | 2.9 | 269 |
| depressionSignal | 141 | 3.0 | 2.6 | 194 |
| drug ineffectiveSignal | 769 | 2.9 | 2.7 | 995 |
| insomniaSignal | 147 | 2.7 | 2.3 | 159 |
| vomiting | 141 | 1.5 | 1.3 | 21 |
| headache | 188 | 1.5 | 1.3 | 29 |
| dizziness | 130 | 1.3 | 1.1 | 8 |
| nausea | 206 | 1.3 | 1.1 | 13 |
| fatigue | 176 | 1.1 | 1.0 | 2 |
| off label use | 150 | 0.8 | 0.7 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.